CardioVascular Research Foundation, Korea   Report issue

Foundation Phase 3 Phase 4
Founded: Seoul Korea, Republic of (2002)

Organization Overview

First Clinical Trial
2005
NCT00433966
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CardioVascular Research Foundation, Korea

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina Pectoris (Phase 4)

Angina Pectoris, Variant (Phase 4)

Angina, Stable (Phase 4)

Aortic Valve Stenosis (Phase 4)

Arteriosclerosis (Phase 4)

Atrial Fibrillation (Phase 4)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronary Stenosis (Phase 4)

Heart Diseases (Phase 4)

Infarction (Phase 3)

Inflammation (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 4)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 4)

Plaque, Atherosclerotic (Phase 4)

Syndrome (Phase 4)

Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 16